AUROBINDO PHARMA

Company History

Aurobindo Pharma was born of a vision. Founded in 1986 by Mr. P.V.Ramaprasad Reddy, Mr. K.Nityananda Reddy and a small, highly committed group of professionals, the company became a public venture in 1992. It commenced operations in 1988-89 with a single unit manufacturing semi synthetic penicillins (SSPs) at Pondicherry.

Aurobindo Pharma had gone public in 1995 by listing its shares in various stock exchanges in the country. The company is the market leader in semi-synthetic penicillin drugs. It has a presence in key therapeutic segments like SSPs, cephalosporins, antivirals, CNS, cardio-vascular, gastroenterology, etc.

Over the years, the Aurobindo Pharma has evolved into a knowledge driven company. It is R&D focused, has a multi-product portfolio with multi-country manufacturing facilities, and is becoming a marketing conglomerate across the world.

Aurobindo Pharma created a name for itself in the manufacture of bulk actives, its area of core competence. After ensuring a firm foundation of cost effective production capabilities and a clutch of loyal customers, the company has entered the high margin speciality generic formulations segment, with a global marketing network.

The formulation business is systematically organised with a divisional structure, and has a focused team for each key international market. Aurobindo believes in gaining volume and market share in every business/segment it enters.

Aurobindo has invested significant resources in building a mega infrastructure for APIs and formulations to emerge as a vertically integrated pharmaceutical company. Aurobindo’s five units for APIs and four units for formulations are designed for the regulated markets.

Board of Directors Mr. P.V.Ramaprasad Reddy, (50) Chairman Mr. K.Nityananda Reddy, (50) Managing Director Mr. M. Madan Mohan Reddy, (48) Whole-time Director Dr. M.Sivakumaran, (65) Whole-time Director Mr. M.Sitarama Murthy, (64) Non-Executive Director Dr.P.L.Sanjeev Reddy, (68) Non-Executive Director Dr. D. Rajagopala Redddy, (50) Non-Executive Director Dr. K. Ramachandran, (52) Non-Executive Director Mr.K.Ragunathan, (45) Non-Executive Director Mr.P.Sarath Chandra Reddy, (23) Business Strategy The robustness of business strategies are reviewed by the management at regular intervals. The business plans are modified and improvements made as an ongoing process. The medium term strategy of Aurobindo Pharma is to continuously globalise the intellectual property assets and enhance value to shareholders and customers. In global markets, the Company shall retain and enhance cost efficient quality leadership in semi synthetic penicillins, cephalosporins, newer anti infectives and lifestyle disease drugs. It is the endeavour of the Company to achieve this by resolving complex chemistry challenges, improving process efficiencies, adopting global scale manufacturing and using cost effective market networks throughout South East Asia, Africa and Latin America. Aurobindo Pharma shall repeat its success and emerge as a major player in regulated markets. The Company will obtain regulatory approvals by filing Drug Master Files (DMF) and Abbreviated New Drug Applications (ANDA) in lifestyle disease drugs and sterile and non-sterile cephalosporins having substantial entry barriers. The Company’s competitive advantage is in capturing a large portfolio of approvals, backed up by a global standard R&D effort that offers several patented non-infringing processes and intellectual properties, and a cost efficient mega manufacturing environment complying to US FDA and EU authorities. The Company shall forge alliances with original research companies in the area of custom synthesis. The existing relationships and credibility will help Aurobindo Pharma to acquire a significant part of bulk manufacturing of original research companies into its units. The corporate plans are to ensure growth through organic means, and by adopting strategic joint ventures and alliances. The objective is to maximize the revenues and reduce risks.